Drug Trial Radar · NCT07805551
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Aug 2030
Study completion Aug 2032
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants with advanced CRC. The study is divided into two periods: dose escalation (Phase Ib) and dose expansion (Phase II). Phase Ib of this study is a dose-finding study of different HDM2017 combination therapies. The Phase II study will be conducted at a dose determined to be safe and potentially effective in Phase Ib.
Conditions
- CRC, Colorectal Cancer
Interventions
HDM2017Drug
Administered with continuing until protocol-specified criteria for treatment discontinuation are met
BevacizumabDrug
administered with continuing until protocol-specified criteria for treatment discontinuation are met
OxaliplatinDrug
administered with continuing until protocol-specified criteria for treatment discontinuation are met
FluorouracilDrug
administered with continuing until protocol-specified criteria for treatment discontinuation are met
CapecitabineDrug
administered with continuing until protocol-specified criteria for treatment discontinuation are met
LeucovorinDrug
administered with dosing continuing until protocol-specified criteria for treatment discontinuation are met
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP
- Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
- Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP
- Objective Response Rate (ORR)Time frame: From date of first-dosing until the date of first documented progression or date of 30 days after the last dose of IMP, whichever came first, assessed up to about 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.